×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北京... [6]
吉林大学白求恩第一医... [5]
复旦大学上海医学院 [5]
中南大学 [2]
合肥物质科学研究院 [2]
西安交通大学 [1]
更多...
内容类型
期刊论文 [19]
会议论文 [3]
发表日期
2022 [1]
2021 [1]
2019 [5]
2018 [9]
2016 [5]
2011 [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共22条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
提交时间升序
提交时间降序
题名升序
题名降序
作者升序
作者降序
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
期刊论文
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 卷号: 14
作者:
Yan, Min
;
Yuan, Peng
;
Ouyang, Quchang
;
Cheng, Ying
;
Han, Guohui
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2022/12/23
breast cancer
chemotherapy
efficacy
lobaplatin
neoplasm metastasis
safety
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:
Yan, Min
;
Ouyang, Quchang
;
Sun, Tao
;
Niu, Limin
;
Yang, Jin
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2022/01/10
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
期刊论文
EUROPEAN JOURNAL OF CANCER, 2019, 卷号: 112
作者:
Zhang, Qingyuan
;
Xu, Binghe
;
Funasaka, Setsuo
;
Saito, Kenichi
;
Hiraiwa, Masahide
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2019/12/05
Progression-free survival
Tolerability
Locally recurrent or metastatic breast cancer
Eribulin
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
期刊论文
EUROPEAN JOURNAL OF CANCER, 2019, 卷号: 112
作者:
Yuan, Peng
;
Hu, Xichun
;
Sun, Tao
;
Li, Wei
;
Zhang, Qingyuan
收藏
  |  
浏览/下载:19/0
  |  
提交时间:2019/12/05
Progression-free survival
Tolerability
Locally recurrent or metastatic breast cancer
Eribulin
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
期刊论文
LANCET ONCOLOGY, 2019, 卷号: 20, 期号: 6
作者:
Jiang, Zefei
;
Li, Wei
;
Hu, Xichun
;
Zhang, Qingyuan
;
Sun, Tao
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2019/12/05
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
期刊论文
2019, 卷号: 37, 期号: 29, 页码: 2610-2619
作者:
Ma Fei
;
Ouyang Quchang
;
Li Wei
;
Jiang Zefei
;
Tong Zhongsheng
收藏
  |  
浏览/下载:32/0
  |  
提交时间:2020/01/03
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
期刊论文
2019, 卷号: 112, 页码: 57-65
作者:
Yuan, Peng
;
Hu, Xichun
;
Sun, Tao
;
Li, Wei
;
Zhang, Qingyuan
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2020/01/03
Progression-free survival
Tolerability
Locally recurrent or metastatic breast cancer
Eribulin
A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Xu, Binghe
;
Ma, Fei
;
Ouyang, Quchang
;
Li, Wei
;
Jiang, Zefei
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2019/12/05
Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Li, Wei
;
Im, Seock-Ah
;
Xu, Binghe
;
Robson, Mark
;
Ouyang, Quchang
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2019/12/05
Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Im, Seock-Ah
;
Xu, Binghe
;
Li, Wei
;
Robson, Mark
;
Ouyang, Quchang
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2019/12/05
©版权所有 ©2017 CSpace - Powered by
CSpace